Augmenting prolonged exposure (PE) with pharmacotherapy has been suggested as a promising
solution to address treatment-resistant PTSD and high dropout rates. Ketamine has
been shown to have rapid-acting effects on treatment resistant depression following
single infusion and with neurogenesis, that may promote new learning. We present first
results of ketamine augmentation of intensive 7-day-PE (KPE) for PTSD patients.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Biological PsychiatryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2019 Published by Elsevier Inc.
